Business Wire

Hirslanden Clinique La Colline Adopts Medacta’s Efficiency KneePack: the New Gold Standard in Resource Optimization and Knee Replacement Procedure Management

Del

Hirslanden Clinique La Colline, an internationally renowned clinic in Geneva and part of the first Swiss private clinic group Hirslanden, has optimized instrument management and implant stock for its total knee replacement (TKR) procedures by introducing Medacta’s Efficiency KneePack as the new standard in its practice. This advanced solution has helped Clinique La Colline to improve its supply chain and TKR procedure workflow, reducing the resources needed to manage procedures and enabling an even stronger focus on surgeons’ needs and patients’ wellbeing.

“I was already using Medacta’s MyKnee Patient-Specific cutting blocks, which have helped me achieve higher dependability with greater ease and comfort of use in every case,” said Dr. med. Jean-Philippe Corsat.

“The Single Use Instruments, delivered brand new and unworn every time, have been a great addition,” added Dr. med. Marc Saudan. “I didn’t have to change my technique at all; after a few cases, I was completely used to them.”

Delivered sterile and ready for use, the Efficiency KneePack is the ultimate solution to implant Medacta’s GMK® Primary or GMK® Sphere in a TKR procedure. The Efficiency KneePack includes femur and tibia implants, MyKnee® Patient-Matched cutting blocks and GMK® Efficiency single use instruments.

“Thanks to Medacta’s Efficiency KneePack, we have drastically streamlined our logistic workflow,” said André Joyeusaz, a Hirslanden Clinique La Colline logistics department representative. “Instrumentation sets and implants are delivered just a few days before surgery, limiting the stock here at the surgical unit. Everything we need is packaged together, minimizing any source of error and helping us more swiftly to manage the logistics. This is very important on busy days. Any problem related to lost or worn out instruments has been eliminated, including paperwork.”

“The first thing that I noticed was that these instruments are much lighter than the metal ones,” said Veronique Guerraz, a perioperative nurse at the clinic. “They are also very intuitive to assemble and require less thought process to set them up. I can quickly find the instruments needed at each surgical step thanks to their different colors and the organized layout. The packaged sets arrive already sterile and organized, so we do not have to check them before surgery; we can just open the blisters and start using the instruments.”

In order to facilitate the best possible outcomes, Medacta utilizes pre-operative computer-based surgical planning software to deliver exactly what is needed for the surgical procedure, including the Efficiency Instruments and implants. This minimizes inventory constraints and provides the necessary inventory to complete the specific surgical procedure.

“It is Medacta’s mission to address surgeon and hospital needs with advanced technologies that encourage patient wellbeing and healthcare system sustainability,” said Francesco Siccardi, Executive Vice President of Medacta International. “The Efficiency KneePack embodies this as it addresses pain points at every level. We believe it will become the gold standard for clinics and ambulatory surgical centers looking to optimize their resources.”

Clinique La Colline is the first center to use Medacta’s Efficiency KneePack, and other centers are now following suit.

About Medacta ® International

Medacta® International is a world leading manufacturer of orthopedic implants, neurosurgical systems, and instrumentation. Medacta’s revolutionary approach and responsible innovation have resulted in standard of care breakthroughs in hip replacement with the AMIS® system and total knee replacement with MyKnee® patient matched technology. Over the last 10 years, Medacta has grown dramatically by taking a holistic approach and placing value on all aspects of the care experience from design to training to sustainability. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 30 countries.

To learn more about Medacta International, please visit: https://www.medacta.com.

Contact information

for Medacta International
Jill Bongiorni, 516-729-2250
Jill@torchcomllc.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00Pressemelding

AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23

New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20Pressemelding

AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute

Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11Pressemelding

The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other

Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn17.11.2017 16:20Pressemelding

Madison Realty Capital (MRC) announced the closing of a $64.0 million construction loan for 200 Kent Avenue, a 117,326 square foot mixed-use development located in Williamsburg, Brooklyn. The retail portion of the property, which will include over 600 feet of frontage, will be anchored by a popular national grocery chain. Overall, the project will offer 50,101 square feet of retail space, 22,055 square feet of office and restaurant space, and 45,170 square feet of parking. “We continue to establish MRC as the one-stop shop for financing transitional real estate, including ground-up development deals like 200 Kent Avenue,” said Josh Zegen, Co-Founder and Managing Principal of MRC. “In this case, we’re working with a repeat MRC borrower who understands our ability to execute efficiently, given our firm’s up-to-the minute knowledge of local market conditions and non-bureaucratic approach to

Ncardia Announces Completion of €10.5M Investment Round17.11.2017 12:31Pressemelding

Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural solutions based on its best-in-class human induced pluripotent stem cell (iPSC)-derived technology, today announced the completion of a €10.5 million series B financing round. The round was led by Épimède, a Belgium venture capital firm. Ncardia is a privately-held company with operations in Europe and the US, that produces and commercializes high-quality, fully-functional human iPSC-derived cardiovascular and neuronal cell types. Using its cell products, Ncardia develops and commercializes assay services for drug safety and efficacy testing. Additionally the company has built up a strong portfolio of patents covering the use of stem cell models for these applications. Stefan Braam, CEO of Ncardia, commented: “At Ncardia, important progress h

Double Win for Vocalink at the 2017 Payments Awards17.11.2017 09:35Pressemelding

Vocalink, a Mastercard company, was last night awarded with two prestigious awards - The Overall Winner and the Payments Infrastructure of the Year Award, for its leading technology and expertise, and in recognition for a milestone year that saw Vocalink’s solutions transform the way people and businesses move money across the globe. 2017 saw Vocalink deliver ground-breaking immediate payments solutions both in the US and Thailand as well as enabling access to the UK payments industry through their payments gateway solution PayPort. The business also saw the launch of the new image based cheque clearing system, creating a robust and more efficient system in the UK. RTP ® in the US: This week, Vocalink announced the launch of RTP® (Real-Time Payments) in the US on behalf of The Clearing House; one of the most comprehensive real-tim

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom